You are here

  • Home
  • Archive
  • Volume 11, Issue 1
  • Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

 

Online download statistics by month:

Online download statistics by month: January 2023 to September 2025

AbstractFullPdf
Jan 2023674683145
Feb 2023341355111
Mar 202318820162
Apr 202314614755
May 202312512641
Jun 202311811844
Jul 202310610637
Aug 202315915836
Sep 202311311345
Oct 2023656517
Nov 2023878721
Dec 2023848633
Jan 2024565834
Feb 2024474720
Mar 2024595952
Apr 2024383931
May 2024475028
Jun 2024646330
Jul 2024636430
Aug 2024423916
Sep 2024404027
Oct 2024787842
Nov 2024747537
Dec 202410410937
Jan 2025838327
Feb 202514014029
Mar 2025838335
Apr 2025868724
May 2025818224
Jun 2025545525
Jul 2025110
Sep 2025110
Total344734981195